Toca 6 Trial Data Update: Tocagen Inc. (NASDAQ: TOCA)

Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today is presenting data describing the tumor microenvironment and immunogenicity  of Toca 511 (vocimagene amiretrorepvec) & Toca FC (flucytosine, extended-release) in patients with solid tumor malignancies at the International Cancer Immunotherapy Conference hosted by The Cancer Research Institute (CRI), the Association for Cancer Immunotherapy (CIMT), the European Academy of Tumor Immunology (EATI), and the American Association for Cancer Research (AACR)  in New York City. The lead author is Jaime Merchan, M.D., director, Phase 1 clinical trials program at Sylvester Comprehensive Cancer Center; associate professor of medicine at the University of Miami Miller School of Medicine.

The poster describes data available as of August 31st for 20 patients with advanced solid tumors, counting colorectal, sarcoma, pancreas and non-small cell lung cancer, treated with intravenous Toca 511 followed by oral Toca FC in the Phase 1b Toca 6 clinical trial. Among these patients, 15 also received Toca 511 via intratumoral administration.

In this preliminary analysis of immune activation in patients with advanced solid tumors, analysis of peripheral blood shows immune cell modulation that is consistent with what has been observed in preclinical studies and in patients with recurrent high grade glioma treated with Toca 511 & Toca FC in previous clinical trials. In addition, available tumor samples from three patients show Toca 511 infected both “hot” (T cells present) and “cold” (T cells low or absent) areas of metastatic tumor, suggesting Toca 511 can penetrate multiple tumor microenvironments. Toca 511 & Toca FC treatment was well tolerated.

“The encouraging preliminary immune activity data from the Toca 6 trial continue to support the projected mechanism of action for Toca 511 & Toca FC and its potentbiial in the treatment of multiple cancers,” said Asha Das, M.D., chief medical officer of Tocagen. “We look forward to advancing expansion opportunities for our lead product in patients with solid tumors.”

Leave a Reply

Your email address will not be published. Required fields are marked *